View ValuationFMC 将来の成長Future 基準チェック /36FMC利益と収益がそれぞれ年間99.9%と4.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に12.4% 99.1%なると予測されています。主要情報99.9%収益成長率99.12%EPS成長率Chemicals 収益成長20.7%収益成長率4.8%将来の株主資本利益率12.37%アナリストカバレッジGood最終更新日11 May 2026今後の成長に関する最新情報お知らせ • Feb 05FMC Corporation Provides Earnings Guidance for the First Quarter and Full Year 2026FMC Corporation provides earnings guidance for the first quarter and full year 2026. For the quarter, the company expects revenue excluding India guidance is between $725 million and $775 million, a decline of 5 % at the midpoint versus prior year driven by a mid-single digit price headwind. For the year, the company expects revenue excluding India guidance is $3.60 billion to $3.80 billion, a decline of 5 % at the midpoint versus prior year.お知らせ • Aug 02FMC Corporation Provides Earnings Guidance for the Third Quarter, Fourth Quarter and Second Half of 2025 and Reaffirms Earnings Guidance for the Full Year 2025FMC Corporation provided earnings guidance for the third quarter, fourth quarter and second half of 2025 and reaffirmed earnings guidance for the full year 2025. For the third quarter, the company expects revenue to be in the range of $1.00 billion to $1.10 billion. For the fourth quarter, the company expects revenue to be in the range of $1.24 billion to $1.34 billion. For the second half, the company expects revenue to be in the range of $2.24 billion to $2.44 billion. For the year, the company expects revenue to be in the range of $4.08 billion to $4.28 billion.すべての更新を表示Recent updatesDeclared Dividend • May 02Dividend of US$0.08 announcedShareholders will receive a dividend of US$0.08. Ex-date: 29th June 2026 Payment date: 16th July 2026 Dividend yield will be 1.6%, which is lower than the industry average of 2.8%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments.Reported Earnings • Apr 30First quarter 2026 earnings released: US$2.09 loss per share (vs US$0.068 loss in 1Q 2025)First quarter 2026 results: US$2.09 loss per share (further deteriorated from US$0.068 loss in 1Q 2025). Revenue: US$758.6m (down 4.1% from 1Q 2025). Net loss: US$261.4m (loss widened US$252.9m from 1Q 2025). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Chemicals industry in Italy.お知らせ • Apr 29FMC Corporation Declares Quarterly Dividend, Payable on July 16, 2026FMC Corporation announced that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.Buy Or Sell Opportunity • Apr 21Now 25% undervaluedThe stock has been flat over the last 90 days, currently trading at €13.54. The fair value is estimated to be €18.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Apr 07FMC Corporation Secures Approval for Isoflex Active in the European UnionFMC Corporation announced that Isoflex active, the trade name for bixlozone, has received regulatory approval in the European Union (EU). This approval is a critical milestone in FMC's commercialization process, paving the way for the introduction of formulated products across more than 55 million planted hectares of cereals, corn, oilseed rape and potato in the EU. Product dossiers have been submitted for these crops, and pending regulatory decisions, FMC anticipates launching products powered by Isoflex active beginning in 2027. Isoflex active is classified by the Herbicide Resistance Action Committee (HRAC) as a Group 13 herbicide. The molecule provides lasting control of key grass weeds and a wide range of broadleaf weeds, offering growers a new mode of action in cereals, enabling them to effectively manage resistant weed populations and protect economically important crops across the EU. The European launches will build on FMC's global rollout of products powered by Isoflex active, which have already been registered and commercialized in Argentina, Australia, Brazil, Chile, China, Great Britain, Pakistan, Uruguay and India. Products containing Isoflex active have exhibited pre-plant, pre-emergence and early post-emergence selectivity in major crops across the globe, including cereals, cotton, oilseed rape, rice and pulses. Research and development on the use of Isoflex active in additional crops and segments is ongoing.お知らせ • Mar 25FMC Corporation to Report Q1, 2026 Results on Apr 29, 2026FMC Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026Upcoming Dividend • Mar 23Upcoming dividend of US$0.08 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 16 April 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Italian dividend payers (5.0%). Lower than average of industry peers (3.7%).Recent Insider Transactions • Mar 08Insider recently bought €215k worth of stockOn the 4th of March, Michael Barry bought around 18k shares on-market at roughly €11.89 per share. This transaction increased Michael Barry's direct individual holding by 12x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €368k more in shares than they have sold in the last 12 months.お知らせ • Feb 28+ 1 more updateFMC Corporation Declares Quarterly Dividend, Payable on April 16, 2026FMC Corporation announced that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on April 16, 2026, to shareholders of record as of the close of business on March 31, 2026.お知らせ • Feb 24FMC Corporation Receives Industry's First Dual Mode of Action Herbicide Classification for RimisoxafenFMC Corporation announced that the Herbicide Resistance Action Committee (HRAC) has classified rimisoxafen as a dual mode of action herbicide, designated under HRAC Groups 12 and 32. This is the first dual mode of action classification in HRAC's history, a significant milestone for the global crop protection industry and validation of FMC's innovative approach to combating herbicide-resistant weeds. The unprecedented classification recognizes rimisoxafen's unique ability to simultaneously inhibit both phytoene desaturase (PDS) and solanesyl diphosphate synthase (SDPS), two critical biochemical pathways in weeds. The dual mode of action makes it far more difficult for weeds to survive and adapt, providing a critical new tool in the fight against herbicide resistance. Herbicide resistance has become an increasingly serious challenge for global agriculture. Palmer amaranth, one of the most economically damaging weed threats facing growers, has developed resistance to eight different herbicide modes of action. Rimisoxafen's dual mode of action creates a significantly higher barrier to resistance development compared to single mode of action herbicides. Rimisoxafen is designed primarily for use in broadacre crops such as corn, soybean, cereals, pulses and sunflower, and will provide effective control of troublesome and resistant broadleaf weeds. Discovered by FMC scientists at the company's Stine Research Center, rimisoxafen represents the third novel herbicide that FMC has developed for regulatory submission in recent years, following Isoflex® active and Dodhylex™ active. FMC expects to begin submitting regulatory dossiers for rimisoxafen in key markets starting in 2026, marking the next step toward bringing this novel technology to growers in key global markets.Reported Earnings • Feb 05Full year 2025 earnings released: US$17.59 loss per share (vs US$3.21 profit in FY 2024)Full year 2025 results: US$17.59 loss per share (down from US$3.21 profit in FY 2024). Revenue: US$3.47b (down 18% from FY 2024). Net loss: US$2.20b (down US$2.60b from profit in FY 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Chemicals industry in Italy.お知らせ • Feb 05FMC Corporation Provides Earnings Guidance for the First Quarter and Full Year 2026FMC Corporation provides earnings guidance for the first quarter and full year 2026. For the quarter, the company expects revenue excluding India guidance is between $725 million and $775 million, a decline of 5 % at the midpoint versus prior year driven by a mid-single digit price headwind. For the year, the company expects revenue excluding India guidance is $3.60 billion to $3.80 billion, a decline of 5 % at the midpoint versus prior year.お知らせ • Jan 23FMC Corporation, Annual General Meeting, Apr 28, 2026FMC Corporation, Annual General Meeting, Apr 28, 2026.お知らせ • Dec 23FMC Corporation to Report Q4, 2025 Results on Feb 04, 2026FMC Corporation announced that they will report Q4, 2025 results After-Market on Feb 04, 2026Declared Dividend • Dec 17Dividend of US$0.08 announcedShareholders will receive a dividend of US$0.08. Ex-date: 30th December 2025 Payment date: 15th January 2026 Dividend yield will be 9.6%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.お知らせ • Dec 13FMC Corporation Declares Quarterly Dividend, Payable on January 15, 2026FMC Corporation announced that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on January 15, 2026, to shareholders of record as of the close of business on December 31, 2025.お知らせ • Dec 05FMC Corporation Announces Resignation of Anthony DiSilvestro from Board of Directors, Effective December 3, 2025FMC Corporation announced that on December 3, 2025, Anthony DiSilvestro notified FMC Corporation of his resignation from the Board of Directors and all committees thereof, effective immediately, due to his increased professional commitments following his appointment as Chief Financial Officer of Keurig Dr Pepper Inc. on November 25, 2025, as well as scheduling conflicts with FMC Board and committee meeting dates.Reported Earnings • Oct 30Third quarter 2025 earnings released: US$4.38 loss per share (vs US$0.53 profit in 3Q 2024)Third quarter 2025 results: US$4.38 loss per share (down from US$0.53 profit in 3Q 2024). Revenue: US$542.2m (down 49% from 3Q 2024). Net loss: US$548.9m (down US$614.6m from profit in 3Q 2024). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Chemicals industry in Italy.Buy Or Sell Opportunity • Oct 30Now 42% undervalued after recent price dropOver the last 90 days, the stock has fallen 56% to €14.47. The fair value is estimated to be €24.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Oct 30+ 2 more updatesRonaldo Pereira to Step Down as President of FMC Corporation, Effective December 15, 2025FMC Corporation announced that Ronaldo Pereira, president, will be stepping down from his position, effective December 15, 2025. The decision was reached by mutual agreement between Pereira and Pierre Brondeau, chairman and chief executive officer. Pereira will be available in an advisory capacity until December 15, to ensure a smooth transition of responsibilities.お知らせ • Sep 26FMC Corporation to Report Q3, 2025 Results on Oct 29, 2025FMC Corporation announced that they will report Q3, 2025 results After-Market on Oct 29, 2025Reported Earnings • Aug 04Second quarter 2025 earnings released: EPS: US$0.34 (vs US$2.38 in 2Q 2024)Second quarter 2025 results: EPS: US$0.34 (down from US$2.38 in 2Q 2024). Revenue: US$1.05b (up 1.2% from 2Q 2024). Net income: US$43.1m (down 86% from 2Q 2024). Profit margin: 4.1% (down from 29% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Chemicals industry in Italy.お知らせ • Aug 02FMC Corporation Provides Earnings Guidance for the Third Quarter, Fourth Quarter and Second Half of 2025 and Reaffirms Earnings Guidance for the Full Year 2025FMC Corporation provided earnings guidance for the third quarter, fourth quarter and second half of 2025 and reaffirmed earnings guidance for the full year 2025. For the third quarter, the company expects revenue to be in the range of $1.00 billion to $1.10 billion. For the fourth quarter, the company expects revenue to be in the range of $1.24 billion to $1.34 billion. For the second half, the company expects revenue to be in the range of $2.24 billion to $2.44 billion. For the year, the company expects revenue to be in the range of $4.08 billion to $4.28 billion.お知らせ • Aug 01FMC Corporation Obtains Registration in Great Britain for Fundatis®? Herbicide Powered by Isoflex®? ActiveFMC Corporation announced it has received registration for Fundatis®? herbicide powered by Isoflex®? active in Great Britain for use in winter wheat and winter barley. Isoflex®? active is a novel herbicide when used in cereals and is classified by the Herbicide Resistance Action Committee (HRAC) as a Group 13 herbicide. Fundatis®? herbicide provides growers with a new tool to help manage herbicide resistance across a wide range of agronomic practices. Fundatis®? herb prevention combines FMC's innovative molecule Isoflex®? active with beflubutamid, providing growers with a new tool for resistance management. Fundatis®? herbicides provides a strong foundation as part of an integrated flower management program, effectively contributing to the control of key annual grass weeds, including Blackgrass (Alopecurus myosuroides) and Italian Ryegrass (Lolium multiflorum). It also offers control of key broadleaf weeds such as Groundsel (Senecio vulgaris) and Speedwell (Veronica spp.). Fundatis®? herbicide will be available to growers during the fall growing season in Great Britain. The registration in Great Britain marks another significant regulatory approval for FMC and Isoflex®? active, which has already been registered and commercialized in Argentina, Australia, Brazil, Chile, China, Pakistan, Uruguay and India. FMC has also submitted a regulatory application for Isoflex®? active In the European Union. Products containing Isoflex®? active have exhibited pre-plant, pre-emergence and early post-emergence selectivity in major crops across the globe, including canola, cereals, oilseed rape and pulses. Research on the use of Isoflex®? activein additional crops and segments is ongoing.お知らせ • Jul 17FMC Corporation Declares a Quarterly Dividend, Payable on October 16, 2025FMC Corporation announced that its board of directors declared a regular quarterly dividend of 58 cents per share, payable on October 16, 2025, to shareholders of record as of the close of business on September 30, 2025.お知らせ • Jul 01FMC Corporation Expands Novel Fluindapyr Fungicide Technology to EMEA RegionFMC Corporation announced regulatory approval for Tremisia fungicide in Ukraine, marking the first introduction of the company's novel fluindapyr technology in the European, Middle East, and Africa (EMEA) region. The approval covers oilseed rape, sunflower, and wheat across more than 10 million hectares of Ukrainian farmland. Tremisia fungicides combines FMC's proprietary fluindapyr molecule with flutriafol, delivering a dual mode of action to help maintain a healthy crop for an extended period. This fungicide targets a broad spectrum of economically significant diseases, including Alternaria and Sclerotinia in sunflower, and Septoria and rust in wheat. The Ukraine registration builds on FMC's successful commercialization of fluindapyr-based products in Argentina, Brazil, Mexico, Paraguay, South Korea, and the United States, with conditional approval secured in the Philippines earlier this year. Pending regulatory decisions, FMC anticipates launching fluindapyr-based product in Bolivia, Chile, Colombia, Honduras, and India, further expanding global access to this innovative fungicide technology.お知らせ • Jun 20FMC Corporation to Report Q2, 2025 Results on Jul 30, 2025FMC Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025お知らせ • Apr 30+ 1 more updateFmc Corporation Declares Quarterly Dividend, Payable on July 17, 2025FMC Corporation announced that its board of directors declared a regular quarterly dividend of 58 cents per share, payable on July 17, 2025, to shareholders of record as of the close of business on June 30, 2025.業績と収益の成長予測BIT:1FMC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20284,0102852413421112/31/20273,8582651962411612/31/20263,6952275591163/31/20263,435-2,456-220-138N/A12/31/20253,467-2,203-176-80N/A9/30/20253,608-482-407-317N/A6/30/20254,132130-4932N/A3/31/20254,120383198277N/A12/31/20244,246402603671N/A9/30/20244,1681,526496564N/A6/30/20244,0841,465405491N/A3/31/20244,0611,220208313N/A12/31/20234,4871,417-520-386N/A9/30/20234,963593-197-61N/A6/30/20235,358724132269N/A3/31/20235,796817195327N/A12/31/20225,802832447582N/A9/30/20225,594730426540N/A6/30/20225,411762350458N/A3/31/20225,200838407514N/A12/31/20215,045806726820N/A9/30/20214,784621436645N/A6/30/20214,674582467670N/A3/31/20214,588556473673N/A12/31/20204,642579485648N/A9/30/20204,687568534706N/A6/30/20204,617550435620N/A3/31/20204,668547241437N/A12/31/20194,610539N/A489N/A9/30/20194,512663N/A-16N/A6/30/20194,421600N/A-50N/A3/31/20194,370504N/A170N/A12/31/20184,285526N/A368N/A9/30/20184,166124N/A430N/A6/30/20183,888145N/A269N/A3/31/20183,39197N/A292N/A12/31/20172,531-136N/A336N/A9/30/20172,587171N/A429N/A6/30/20172,570150N/A533N/A3/31/20172,529147N/A363N/A12/31/20162,539128N/A498N/A9/30/20162,750-63N/A341N/A6/30/20162,952-109N/A39N/A3/31/20163,224-101N/A40N/A12/31/20152,491-222N/A-358N/A9/30/20153,26551N/A-138N/A6/30/20153,25398N/A87N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1FMCは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.3% ) よりも高い成長率であると考えられます。収益対市場: 1FMC今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: 1FMC今後 3 年以内に収益を上げることが予想されます。収益対市場: 1FMCの収益 ( 4.8% ) Italian市場 ( 5.6% ) よりも低い成長が予測されています。高い収益成長: 1FMCの収益 ( 4.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1FMCの 自己資本利益率 は、3年後には低くなると予測されています ( 12.4 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 09:53終値2026/05/11 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋FMC Corporation 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。38 アナリスト機関Benjamin KalloBairdBenjamin TheurerBarclaysBenjamin TheurerBarclays35 その他のアナリストを表示
お知らせ • Feb 05FMC Corporation Provides Earnings Guidance for the First Quarter and Full Year 2026FMC Corporation provides earnings guidance for the first quarter and full year 2026. For the quarter, the company expects revenue excluding India guidance is between $725 million and $775 million, a decline of 5 % at the midpoint versus prior year driven by a mid-single digit price headwind. For the year, the company expects revenue excluding India guidance is $3.60 billion to $3.80 billion, a decline of 5 % at the midpoint versus prior year.
お知らせ • Aug 02FMC Corporation Provides Earnings Guidance for the Third Quarter, Fourth Quarter and Second Half of 2025 and Reaffirms Earnings Guidance for the Full Year 2025FMC Corporation provided earnings guidance for the third quarter, fourth quarter and second half of 2025 and reaffirmed earnings guidance for the full year 2025. For the third quarter, the company expects revenue to be in the range of $1.00 billion to $1.10 billion. For the fourth quarter, the company expects revenue to be in the range of $1.24 billion to $1.34 billion. For the second half, the company expects revenue to be in the range of $2.24 billion to $2.44 billion. For the year, the company expects revenue to be in the range of $4.08 billion to $4.28 billion.
Declared Dividend • May 02Dividend of US$0.08 announcedShareholders will receive a dividend of US$0.08. Ex-date: 29th June 2026 Payment date: 16th July 2026 Dividend yield will be 1.6%, which is lower than the industry average of 2.8%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments.
Reported Earnings • Apr 30First quarter 2026 earnings released: US$2.09 loss per share (vs US$0.068 loss in 1Q 2025)First quarter 2026 results: US$2.09 loss per share (further deteriorated from US$0.068 loss in 1Q 2025). Revenue: US$758.6m (down 4.1% from 1Q 2025). Net loss: US$261.4m (loss widened US$252.9m from 1Q 2025). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Chemicals industry in Italy.
お知らせ • Apr 29FMC Corporation Declares Quarterly Dividend, Payable on July 16, 2026FMC Corporation announced that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.
Buy Or Sell Opportunity • Apr 21Now 25% undervaluedThe stock has been flat over the last 90 days, currently trading at €13.54. The fair value is estimated to be €18.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Apr 07FMC Corporation Secures Approval for Isoflex Active in the European UnionFMC Corporation announced that Isoflex active, the trade name for bixlozone, has received regulatory approval in the European Union (EU). This approval is a critical milestone in FMC's commercialization process, paving the way for the introduction of formulated products across more than 55 million planted hectares of cereals, corn, oilseed rape and potato in the EU. Product dossiers have been submitted for these crops, and pending regulatory decisions, FMC anticipates launching products powered by Isoflex active beginning in 2027. Isoflex active is classified by the Herbicide Resistance Action Committee (HRAC) as a Group 13 herbicide. The molecule provides lasting control of key grass weeds and a wide range of broadleaf weeds, offering growers a new mode of action in cereals, enabling them to effectively manage resistant weed populations and protect economically important crops across the EU. The European launches will build on FMC's global rollout of products powered by Isoflex active, which have already been registered and commercialized in Argentina, Australia, Brazil, Chile, China, Great Britain, Pakistan, Uruguay and India. Products containing Isoflex active have exhibited pre-plant, pre-emergence and early post-emergence selectivity in major crops across the globe, including cereals, cotton, oilseed rape, rice and pulses. Research and development on the use of Isoflex active in additional crops and segments is ongoing.
お知らせ • Mar 25FMC Corporation to Report Q1, 2026 Results on Apr 29, 2026FMC Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026
Upcoming Dividend • Mar 23Upcoming dividend of US$0.08 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 16 April 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Italian dividend payers (5.0%). Lower than average of industry peers (3.7%).
Recent Insider Transactions • Mar 08Insider recently bought €215k worth of stockOn the 4th of March, Michael Barry bought around 18k shares on-market at roughly €11.89 per share. This transaction increased Michael Barry's direct individual holding by 12x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €368k more in shares than they have sold in the last 12 months.
お知らせ • Feb 28+ 1 more updateFMC Corporation Declares Quarterly Dividend, Payable on April 16, 2026FMC Corporation announced that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on April 16, 2026, to shareholders of record as of the close of business on March 31, 2026.
お知らせ • Feb 24FMC Corporation Receives Industry's First Dual Mode of Action Herbicide Classification for RimisoxafenFMC Corporation announced that the Herbicide Resistance Action Committee (HRAC) has classified rimisoxafen as a dual mode of action herbicide, designated under HRAC Groups 12 and 32. This is the first dual mode of action classification in HRAC's history, a significant milestone for the global crop protection industry and validation of FMC's innovative approach to combating herbicide-resistant weeds. The unprecedented classification recognizes rimisoxafen's unique ability to simultaneously inhibit both phytoene desaturase (PDS) and solanesyl diphosphate synthase (SDPS), two critical biochemical pathways in weeds. The dual mode of action makes it far more difficult for weeds to survive and adapt, providing a critical new tool in the fight against herbicide resistance. Herbicide resistance has become an increasingly serious challenge for global agriculture. Palmer amaranth, one of the most economically damaging weed threats facing growers, has developed resistance to eight different herbicide modes of action. Rimisoxafen's dual mode of action creates a significantly higher barrier to resistance development compared to single mode of action herbicides. Rimisoxafen is designed primarily for use in broadacre crops such as corn, soybean, cereals, pulses and sunflower, and will provide effective control of troublesome and resistant broadleaf weeds. Discovered by FMC scientists at the company's Stine Research Center, rimisoxafen represents the third novel herbicide that FMC has developed for regulatory submission in recent years, following Isoflex® active and Dodhylex™ active. FMC expects to begin submitting regulatory dossiers for rimisoxafen in key markets starting in 2026, marking the next step toward bringing this novel technology to growers in key global markets.
Reported Earnings • Feb 05Full year 2025 earnings released: US$17.59 loss per share (vs US$3.21 profit in FY 2024)Full year 2025 results: US$17.59 loss per share (down from US$3.21 profit in FY 2024). Revenue: US$3.47b (down 18% from FY 2024). Net loss: US$2.20b (down US$2.60b from profit in FY 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Chemicals industry in Italy.
お知らせ • Feb 05FMC Corporation Provides Earnings Guidance for the First Quarter and Full Year 2026FMC Corporation provides earnings guidance for the first quarter and full year 2026. For the quarter, the company expects revenue excluding India guidance is between $725 million and $775 million, a decline of 5 % at the midpoint versus prior year driven by a mid-single digit price headwind. For the year, the company expects revenue excluding India guidance is $3.60 billion to $3.80 billion, a decline of 5 % at the midpoint versus prior year.
お知らせ • Jan 23FMC Corporation, Annual General Meeting, Apr 28, 2026FMC Corporation, Annual General Meeting, Apr 28, 2026.
お知らせ • Dec 23FMC Corporation to Report Q4, 2025 Results on Feb 04, 2026FMC Corporation announced that they will report Q4, 2025 results After-Market on Feb 04, 2026
Declared Dividend • Dec 17Dividend of US$0.08 announcedShareholders will receive a dividend of US$0.08. Ex-date: 30th December 2025 Payment date: 15th January 2026 Dividend yield will be 9.6%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.
お知らせ • Dec 13FMC Corporation Declares Quarterly Dividend, Payable on January 15, 2026FMC Corporation announced that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on January 15, 2026, to shareholders of record as of the close of business on December 31, 2025.
お知らせ • Dec 05FMC Corporation Announces Resignation of Anthony DiSilvestro from Board of Directors, Effective December 3, 2025FMC Corporation announced that on December 3, 2025, Anthony DiSilvestro notified FMC Corporation of his resignation from the Board of Directors and all committees thereof, effective immediately, due to his increased professional commitments following his appointment as Chief Financial Officer of Keurig Dr Pepper Inc. on November 25, 2025, as well as scheduling conflicts with FMC Board and committee meeting dates.
Reported Earnings • Oct 30Third quarter 2025 earnings released: US$4.38 loss per share (vs US$0.53 profit in 3Q 2024)Third quarter 2025 results: US$4.38 loss per share (down from US$0.53 profit in 3Q 2024). Revenue: US$542.2m (down 49% from 3Q 2024). Net loss: US$548.9m (down US$614.6m from profit in 3Q 2024). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Chemicals industry in Italy.
Buy Or Sell Opportunity • Oct 30Now 42% undervalued after recent price dropOver the last 90 days, the stock has fallen 56% to €14.47. The fair value is estimated to be €24.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Oct 30+ 2 more updatesRonaldo Pereira to Step Down as President of FMC Corporation, Effective December 15, 2025FMC Corporation announced that Ronaldo Pereira, president, will be stepping down from his position, effective December 15, 2025. The decision was reached by mutual agreement between Pereira and Pierre Brondeau, chairman and chief executive officer. Pereira will be available in an advisory capacity until December 15, to ensure a smooth transition of responsibilities.
お知らせ • Sep 26FMC Corporation to Report Q3, 2025 Results on Oct 29, 2025FMC Corporation announced that they will report Q3, 2025 results After-Market on Oct 29, 2025
Reported Earnings • Aug 04Second quarter 2025 earnings released: EPS: US$0.34 (vs US$2.38 in 2Q 2024)Second quarter 2025 results: EPS: US$0.34 (down from US$2.38 in 2Q 2024). Revenue: US$1.05b (up 1.2% from 2Q 2024). Net income: US$43.1m (down 86% from 2Q 2024). Profit margin: 4.1% (down from 29% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Chemicals industry in Italy.
お知らせ • Aug 02FMC Corporation Provides Earnings Guidance for the Third Quarter, Fourth Quarter and Second Half of 2025 and Reaffirms Earnings Guidance for the Full Year 2025FMC Corporation provided earnings guidance for the third quarter, fourth quarter and second half of 2025 and reaffirmed earnings guidance for the full year 2025. For the third quarter, the company expects revenue to be in the range of $1.00 billion to $1.10 billion. For the fourth quarter, the company expects revenue to be in the range of $1.24 billion to $1.34 billion. For the second half, the company expects revenue to be in the range of $2.24 billion to $2.44 billion. For the year, the company expects revenue to be in the range of $4.08 billion to $4.28 billion.
お知らせ • Aug 01FMC Corporation Obtains Registration in Great Britain for Fundatis®? Herbicide Powered by Isoflex®? ActiveFMC Corporation announced it has received registration for Fundatis®? herbicide powered by Isoflex®? active in Great Britain for use in winter wheat and winter barley. Isoflex®? active is a novel herbicide when used in cereals and is classified by the Herbicide Resistance Action Committee (HRAC) as a Group 13 herbicide. Fundatis®? herbicide provides growers with a new tool to help manage herbicide resistance across a wide range of agronomic practices. Fundatis®? herb prevention combines FMC's innovative molecule Isoflex®? active with beflubutamid, providing growers with a new tool for resistance management. Fundatis®? herbicides provides a strong foundation as part of an integrated flower management program, effectively contributing to the control of key annual grass weeds, including Blackgrass (Alopecurus myosuroides) and Italian Ryegrass (Lolium multiflorum). It also offers control of key broadleaf weeds such as Groundsel (Senecio vulgaris) and Speedwell (Veronica spp.). Fundatis®? herbicide will be available to growers during the fall growing season in Great Britain. The registration in Great Britain marks another significant regulatory approval for FMC and Isoflex®? active, which has already been registered and commercialized in Argentina, Australia, Brazil, Chile, China, Pakistan, Uruguay and India. FMC has also submitted a regulatory application for Isoflex®? active In the European Union. Products containing Isoflex®? active have exhibited pre-plant, pre-emergence and early post-emergence selectivity in major crops across the globe, including canola, cereals, oilseed rape and pulses. Research on the use of Isoflex®? activein additional crops and segments is ongoing.
お知らせ • Jul 17FMC Corporation Declares a Quarterly Dividend, Payable on October 16, 2025FMC Corporation announced that its board of directors declared a regular quarterly dividend of 58 cents per share, payable on October 16, 2025, to shareholders of record as of the close of business on September 30, 2025.
お知らせ • Jul 01FMC Corporation Expands Novel Fluindapyr Fungicide Technology to EMEA RegionFMC Corporation announced regulatory approval for Tremisia fungicide in Ukraine, marking the first introduction of the company's novel fluindapyr technology in the European, Middle East, and Africa (EMEA) region. The approval covers oilseed rape, sunflower, and wheat across more than 10 million hectares of Ukrainian farmland. Tremisia fungicides combines FMC's proprietary fluindapyr molecule with flutriafol, delivering a dual mode of action to help maintain a healthy crop for an extended period. This fungicide targets a broad spectrum of economically significant diseases, including Alternaria and Sclerotinia in sunflower, and Septoria and rust in wheat. The Ukraine registration builds on FMC's successful commercialization of fluindapyr-based products in Argentina, Brazil, Mexico, Paraguay, South Korea, and the United States, with conditional approval secured in the Philippines earlier this year. Pending regulatory decisions, FMC anticipates launching fluindapyr-based product in Bolivia, Chile, Colombia, Honduras, and India, further expanding global access to this innovative fungicide technology.
お知らせ • Jun 20FMC Corporation to Report Q2, 2025 Results on Jul 30, 2025FMC Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025
お知らせ • Apr 30+ 1 more updateFmc Corporation Declares Quarterly Dividend, Payable on July 17, 2025FMC Corporation announced that its board of directors declared a regular quarterly dividend of 58 cents per share, payable on July 17, 2025, to shareholders of record as of the close of business on June 30, 2025.